Refine by
Advanced Radiotherapy Articles & Analysis
13 news found
The PRIME phantom is an anthropomorphic, 3D-printed head phantom that combines true-to-life human anatomy with advanced point, 2D and 3D dosimetry to deliver true end-to-end quality assurance. ...
ByRTsafe
BOSTON & LJUBLJANA, Slovenia--(BUSINESS WIRE)--Neutron Therapeutics, a targeted radiation therapy company developing a comprehensive solution for Boron Neutron Capture Therapy (BNCT), and Cosylab, the world's leading provider of control systems for the planet's most complex machines, today announced that they have reached their second joint milestone in the clinical commissioning of Neutron ...
The three managers join the company from Novartis, after having worked at Advanced Accelerator Applications (AAA). At the same time, clinical progresses are ongoing for BAT-90, the advanced cancer radiotherapy platform developed by BetaGlue: recently, the first three breast cancer patients have been treated at New Hospitals in Tblisi, Georgia. ...
Betty Polikar, Gianluca De Danieli, Pietro Bubba Bello and Caia Bisaccioni strengthen the Clinical Research, Manufacturing and Quality areas Clinical developments continue on the advanced cancer radiotherapy platform, BAT-90, as the first breast cancer patient was treated Milan, October 19, 2022 - BetaGlue Technologies, a highly innovative company working ...
Theraised capitalwill give BetaGlue Technologies the ability to further develop its advanced radiotherapy platform, BAT-90, thus opening a new chapter in the fight against cancer BetaGlue Technologieshasclosed a EUR 10 million equity financing round:Fin Posillipo(Petrone Group),Kairos Partners SGR,LIFTT(Venture Capital led by Stefano Buono, founder of ...
Fin Posillipo (Petrone Group], Kairos Partners SGR, LIFTT, Neva Sgr (Intesa Sanpaoh Group), Profequycapital and Romedjoined the share capital Innogest Capital and Panakes Partners reinvest The financing will give BetaGlue Technologies the ability to further develop its advanced radiotherapy platform, BAT-90, and accelerate access to the Safe-Biopsy Device ...
The first clinical results have shown that BAT-90 innovative radiotherapy platform makes it possible to treat only the area where the tumour is located, while avoiding the surrounding tissues, so as to combine treatment efficacy and patient safety CEO/CMO, Dr. Antonino Amato, said: "The confirmation in this first patient of the previous findings from the pre-clinical studies with BAT-90 opens ...
BOSTON & LJUBLJANA, Slovenia--(BUSINESS WIRE)--Neutron Therapeutics, a targeted radiation therapy company developing a comprehensive solution for Boron Neutron Capture Therapy (BNCT), and Cosylab, the world’s leading provider of control systems for the planet’s most complex machines, today announced that Neutron Therapeutics' nuBeam® BNCT System, using Cosylab's OncologyOne ...
” Proton therapy, a highly advanced form of radiation therapy, targets tumors with greater precision than traditional x-ray-based radiotherapy and can reduce the amount of unnecessary radiation exposure to vulnerable healthy tissue and organs. ...
Mevion Medical Systems and Proton International announce the selection of the MEVION S250i Proton Therapy System with HYPERSCAN Pencil Beam Scanning (PBS) to equip the UT Health San Antonio Proton Therapy and Research Center. It will be the first proton therapy system in San Antonio and South Texas to provide this advanced alternative to conventional radiation therapy for cancer. Proton ...
(TSE: 6501, ”Hitachi”) today announced that “Shonan Kamakura Advanced Medical Center” at Shonan Kamakura General Hospital of Tokushukai Medical Group, where Hitachi's compact proton therapy system (hereafter, “the system”) has been installed, has commenced treatment with the system on 31 January 2022. This is the first order for Hitachi’s ...
RTsafe, a medical technology company focused on improving the safety and accuracy of radiotherapy for cancer and other medical conditions, today announced that Biomedic Medical Group will be the exclusive distributor of RTsafe’s products in China. We are delighted to announce this new collaboration and looking forward to provide our products to the Chinese ...
ByRTsafe
This agreement extends the radio-oncology portfolio of Debiopharm which currently includes another clinical stage radiotherapeutic and the radiotherapy-enhancing antagonist of lAPs (Inhibitors of Apoptosis proteins) Debio 1143. The collaboration with 3BP, a renowned expert in theranostic peptide discovery and radioconjugates, is projected to advance the program ...